Physician profile
Christopher Mitchell Ray
NPI 1174181929
$41,261.98
in general payments reported to CMS, 2019-2025
25 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $837 · 2022: $9,017 · 2023: $29K · 2024: $1,630 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $5,221 · Food and Beverage: $4,913 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,180.00 |
| Travel and Lodging | $5,220.84 |
| Food and Beverage | $4,912.57 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25,865.30 | 2022-2024 | Imfinzi |
| Exelixis INC. | $6,331.00 | 2021-2022 | |
| Array Biopharma INC | $3,852.96 | 2022-2025 | Braftovi, Tukysa, Mektovi |
| Ipsen Biopharmaceuticals, INC | $953.57 | 2021-2025 | Onivyde, Somatuline Depot |
| Medtronic, INC. | $819.96 | 2022-2025 | Signia, Ligasure |
| Abbvie INC. | $346.04 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $318.92 | 2023-2025 | |
| Novocure INC. | $290.91 | 2024-2025 | Optune Gio, Optune |
| Jazz Pharmaceuticals INC. | $267.68 | 2024-2025 | |
| Genentech, INC. | $250.34 | 2023-2024 | Avastin, Tecentriq |
| Daiichi Sankyo INC. | $244.88 | 2021 | |
| Intera Oncology, INC | $231.82 | 2024 | Intera |
| Pfizer INC. | $209.23 | 2022-2025 | |
| Boston Scientific Corporation | $143.90 | 2023 | Watchman Access System |
| Foundation Medicine, INC. | $127.88 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $121.13 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.13 | 2024 | Fruzaqla |
| Eisai INC. | $117.45 | 2021 | |
| Lilly USA, LLC | $117.23 | 2025 | Retevmo |
| Amgen INC. | $108.96 | 2025 | |
| Baxter Healthcare | $103.20 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $95.62 | 2022 | |
| Seagen INC. | $95.00 | 2025 | |
| Nestle Healthcare Nutrition INC. | $85.71 | 2023 | |
| Aimmune Therapeutics, INC. | $42.16 | 2024-2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.